Per this article https://www.healthrising.org/blog/2025/11/03/glp-1-agonist-mounjaro-chronic-fatigue-fm-long-covid/
MCAS, ME/CFS and conditions in that family appear to be responding well to GLPs. Patients have described substantial symptom improvement — less fatigue, clearer thinking, lower mast cell activation — once these medications were started, even at the low "microdose" end.
A COVID infection left me with circulation problems and neuropathy, both of which have eased. Layering up as carefully as I can, I still could not tolerate time in the cold without my fingers and toes burning or going numb. Personally, 1 wk of tirz at 250mcg has been life changing.
Doctors working in ME/CFS/FM and long-COVID are conservative by nature — conservative not in what they prescribe but in how they bring it in. They phase treatments in gradually so as not to spark a bad reaction. With at least these two doctors, that trial period looks finished, and they are putting them in early in their protocols.
MCAS, ME/CFS and conditions in that family appear to be responding well to GLPs. Patients have described substantial symptom improvement — less fatigue, clearer thinking, lower mast cell activation — once these medications were started, even at the low "microdose" end.
A COVID infection left me with circulation problems and neuropathy, both of which have eased. Layering up as carefully as I can, I still could not tolerate time in the cold without my fingers and toes burning or going numb. Personally, 1 wk of tirz at 250mcg has been life changing.
Doctors working in ME/CFS/FM and long-COVID are conservative by nature — conservative not in what they prescribe but in how they bring it in. They phase treatments in gradually so as not to spark a bad reaction. With at least these two doctors, that trial period looks finished, and they are putting them in early in their protocols.